DGX

Quest Diagnostics Incorporated

HealthcareDiagnostics & ResearchNASDAQ

$196.26

+$0.66 (0.33%)today

Conviction

7/ 10

Fair Value$218.50

Upside+11.33%

Signal7.93

Market Cap$21.9B

52W Range$157.20–$213.50

Next EarningsApr 21

Conviction History

Conviction Changes

No conviction changes recorded

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$207.24

Current Price$195.51

Upside / Down+6.0%

P(Undervalued)61.1%

P(20%+ Up)27.6%

P(15%+ Down)15.6%

Fair Value Distribution — percentile bands

61.1% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

4.6%/yr

±4.0% · revenue growth to justify current price

FCF-Based Reverse DCF

4.7%/yr

±3.2% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

KEY VALUE DRIVERS

Spearman correlation — what moves this valuation most

Bull Case

Queued for analysis

Eagle will generate this view by the next trading session (~7h).

Bear Case

Queued for analysis

Eagle will generate this view by the next trading session (~7h).

Research Feed

sec_10kMar 4

Conviction: unchanged

FY2025 10-K Deep Read: Thesis Intact, Valuation Full Near-Term

Quest FY2025 confirms defensive compounder thesis. $11B revenue stable, Advanced Dx $1B+ growing double-digits. FDA LDT rule vacated (favorable), PAMA delayed to 2026. 15th dividend increase. Stock ne...

sec_10kMar 3

Conviction: unchanged

FY2025 Performance: Strong Core Business, Advanced Diagnostics Growth Outpacing Headwinds

Quest reported stable FY2025 with Advanced Diagnostics and operational efficiency offsetting reimbursement headwinds. Strong market position, B+ Advanced Dx revenue on double-digit growth, AI/automati...